Potassium channels and their emerging role in parkinson's disease

Brain Res Bull. 2020 Jul:160:1-7. doi: 10.1016/j.brainresbull.2020.04.004. Epub 2020 Apr 17.

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder, which is associated with a selective loss of dopaminergic neurons in the substantia nigra (SN) and a reduction of dopamine in the striatum. Recently, ion channel dysfunction has been considered a reason for the pathogenesis of PD. Potassium (K+) channels are widespread in the central nervous system, and play key roles in modulating cellular excitability, synaptic transmission, and neurotransmitter release. Based on recent studies and data, we propose that K+ channels may be new therapeutic targets for PD that slow the progressive loss of dopaminergic neurons and attenuate motor and non-motor symptoms. In this review, we mainly focus on: delayed rectifier, inwardly rectifying, and double-pore K+ channels. We summarize the expression and function of these channels in PD-related brain regions. We also discuss the effects of pharmacological blockade or activation of K+ channels in the progression and treatment of PD.

Keywords: ATP-sensitive K(+)channels; Delayed rectifier K(+)channels; Dopaminergic neurons; Double-Pore K(+)channels; G protein-gated inward rectifying K(+)channels; Parkinson’s disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / metabolism*
  • Humans
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism*
  • Potassium Channel Blockers / pharmacology
  • Potassium Channel Blockers / therapeutic use
  • Potassium Channels / metabolism*
  • Reactive Oxygen Species / metabolism
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism*

Substances

  • Potassium Channel Blockers
  • Potassium Channels
  • Reactive Oxygen Species